In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Sensei Biotherapeutics, with a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Keller has given his Buy rating due to a combination of factors related to the promising results from Sensei Biotherapeutics’ Phase 1/2 trial of solnerstotug. The trial demonstrated notable safety and progression-free survival (PFS) outcomes, particularly in patients with challenging PD-L1 resistant tumors. The higher dose of solnerstotug showed six clinical responses, with five occurring in patients with resistant tumors, and a 6-month PFS rate of 50% in this group, which is a significant improvement over historical benchmarks.
Additionally, the safety profile of solnerstotug was generally well-tolerated, with manageable mild adverse events, supporting its potential for further development. The promising data positions solnerstotug favorably in the CKI space and justifies the planned Phase 2 trials, which aim to further explore its efficacy in specific patient populations. These factors collectively underpin Keller’s optimistic outlook and Buy rating for Sensei Biotherapeutics, as the company progresses with its clinical development plans.